[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"estrogen-receptor-positive-breast-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:estrogen-receptor-positive-breast-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,56,85,107,132,152,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053526","phase-3-testing-whether-hormone-therapy-with-ribociclib-is-as-effective-as-chemotherapy-followed-by-hormone-therapy-with-ribociclib-for-the-treatment-of-high-anatomic-stage-breast-cancer-with-low-recurrence-risk-the-rxfine-low-trial-100053526",false,"NCT07391774","Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos\u002FHER2-neg Breast Cancer With RS≤25 (RxFINE-Low)","Inclusion Criteria:\n\n* STEP 0: Patient must be ≥ 18 years of age\n* STEP 0: Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 28 days prior to Step 0 pre-registration\n* STEP 0: Patient must be a postmenopausal woman or a man\n\n  * NOTE: Menopause can be determined by any of the following:\n\n    * Prior bilateral oophorectomy\n    * Age ≥ 60 years\n    * Age \\\u003C 60 years with amenorrhea for ≥ 12 months and estradiol and follicle stimulating hormone (FSH) levels in the postmenopausal range\n  * NOTE: FSH and estradiol levels should be repeated as clinically indicated to ensure menopausal status in patients with breast cancer with chemotherapy-induced amenorrhea\n* STEP 0: Patient must meet one of the following staging criteria postoperatively according to American Joint Committee on Cancer (AJCC) 8th edition criteria\n\n  * pT0-T3 with 3 positive ipsilateral lymph nodes (micro-or macrometastatic disease) and no planned axillary lymph node dissection after definitive surgery in the breast and axilla with curative intent.\n  * pT0-T3 with N2 or N3\n  * pT3 with N0-N3\n\n    * NOTES:\n\n      * Patients with T4 breast cancer are not eligible.\n      * Positive isolated tumor cells (ITCs) in axillary nodes without micro- or macrometastasis are considered N0 for eligibility purposes.\n      * ITC does not contribute to nodal count for staging purposes\n* STEP 0: Patient must have a primary breast tumor that is estrogen receptor (ER) positive with \\> 10% ER expression by immunohistochemistry (IHC) as per 2020 American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) Estrogen Receptor Testing Guideline.\n\n  * NOTE: ER 1-10% are reported as ER low positive. These tumors have less endocrine-sensitive disease and are not eligible)\n* STEP 0: Patient must have a primary breast tumor that is HER2-negative by current ASCO\u002FCAP guidelines utilizing immunohistochemistry and\u002For fluorescence in situ hybridization (FISH)\n* STEP 0: Patient may have multicentric or multifocal breast cancer if the highest stage tumor meets eligibility criteria outlined above, and the tumor sites are felt to represent a single disease process by local pathology or other sites of disease are also ER-positive (\\> 10%) and HER2 negative, if such testing is completed. If local pathology feels that multicentric or multifocal disease may represent distinct disease processes repeat disease receptor testing is required other sites of disease must also be also ER-positive (\\> 10%) and HER2-negative\n* STEP 0: For patients who have undergone a lumpectomy, the margins of the resected specimen or re-excision must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. Positive posterior margin is allowed if surgeon deems no further resection possible. Patients with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection\n* STEP 0: For patients who have undergone mastectomy, the margins must be free of residual gross tumor. Patients with microscopic positive margins are eligible if post-mastectomy radiation treatment (RT) of the chest wall will be administered\n* STEP 0: Patient must have undergone axillary staging with sentinel lymph node biopsy (SLNB), targeted axillary dissection (TAD), or axillary lymph node dissection (ALND)\n* STEP 0: Patient must have no evidence of locoregional or distant metastatic disease by clinical history and physical exam. Treating physician can consider additional imaging evaluation per National Comprehensive Cancer Network (NCCN) guidelines and\u002For institutional practice\n* STEP 0: Patient must be able to have Oncotype DX testing performed.\n\n  * If Oncotype DX testing was previously performed, the results of Recurrence Score (RS) must be available and must meet Step 1 eligibility criteria.\n  * If Oncotype DX testing was not performed yet, tissue from the core, excisional biopsy or surgical specimen of the tumor lesion must be available and must be shipped to Exact Sciences for determination of the Oncotype DX Recurrence Score (RS) for eligibility and stratification.\n\n    * NOTE: Exact Sciences will notify the submitting institution of Recurrence Score results within two (2) weeks of receipt of the tumor specimen. Institutions will receive an email notification of eligibility status once Recurrence Score results are entered into Rave by the submitting institution\n* STEP 0: Patient must have had their final cancer surgery for breast cancer (including re-excision of margins) less than 16 weeks prior to Step 0 Pre-Registration.\n\n  * NOTE: This excludes additional surgery for reconstructive purposes\n* STEP 0: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* STEP 0: Patients with synchronous DCIS or LCIS are eligible\n* STEP 0: Patient with prior history of ER-negative DCIS diagnosed at least 5 years prior to Step 0 Pre-Registration without evidence of recurrence are eligible\n* STEP 0: Patient must not have a prior history of invasive ER-positive breast cancer. Patients with a history of ER-negative breast cancer are eligible if they were diagnosed at least 5 years prior to Step 0 Pre-Registration and have had no evidence of recurrence\n* STEP 0: Patients must not have received prior endocrine therapy such as tamoxifen, raloxifene, or aromatase inhibitors for chemoprevention within 5 years prior to Step 0 Pre-Registration with the exception of a short course of endocrine therapy of less than 6 weeks duration prior to Step 0 Pre-Registration.\n\n  * NOTE: The Oncotype Dx for study eligibility must be performed on specimen obtained prior to initiation of any endocrine therapy\n* STEP 0: Patient must not be concurrently using systemic hormone replacement therapy (HRT). If receiving HRT at the time of breast cancer diagnosis, this must be discontinued prior to Step 0 Pre-Registration with appropriate washout\n* STEP 0: Absolute neutrophil count (ANC) ≥ 1,500\u002FµL (obtained ≤ 28 days prior to Step 0 Pre-Registration)\n* STEP 0: Hemoglobin ≥ 9.0 g\u002FdL (obtained ≤ 28 days prior to Step 0 Pre-Registration)\n* STEP 0: Platelets ≥ 100,000\u002FµL (obtained ≤ 28 days prior to Step 0 Pre-Registration)\n* STEP 0: Total bilirubin ≤ institutional upper limit of normal (ULN) or \\\u003C 1.5 x ULN for patients who have a bilirubin elevation in patients with well documented Gilbert's disease or similar syndrome involving slow conjugation of bilirubin (obtained ≤ 28 days prior to Step 0 Pre-Registration)\n* STEP 0: Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 2.5 × institutional ULN (obtained ≤ 28 days prior to Step 0 Pre-Registration)\n* STEP 0: Estimated glomerular filtration rate (eGFR) ≥ 30 mL\u002Fminute\u002F1.73 m\\^2 (obtained ≤ 28 days prior to Step 0 Pre-Registration)\n* STEP 0: Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of Step 0 Pre-Registration are eligible for this trial\n* STEP 0: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* STEP 0: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* STEP 0: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2 or better\n* STEP 0: Patient must have a standard 12-lead electrocardiogram (ECG) within 28 days prior to Step 0 Pre-Registration, documenting:\n\n  * QT interval using Fridericia's correction (QTcF) \\\u003C 450 msec.\n  * Resting heart rate 50-90 beats per minute (determined from the ECG)\n* STEP 0: Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available will also be considered eligible\n* STEP 0: Patient must not have comorbidities considered a safety risk for standard adjuvant chemotherapy, endocrine therapy or CDK4\u002F6 inhibitor as per Investigator's discretion\n* STEP 0: Patient must not have a contraindication to adjuvant chemotherapy based on treating physician's discretion\n* STEP 0: Patient must not have received prior chemotherapy for this malignancy\n* STEP 0: Patient must not have received prior CDK4\u002F6 inhibitor\n* STEP 0: Patient must not have a known contraindication to ribociclib per current Food and Drug Administration (FDA) indication\n* STEP 0: Patient must not have a known hypersensitivity to any of the excipients of ribociclib and\u002For endocrine therapy (ET) (e.g. rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, and soy allergy)\n* STEP 0: Males must not expect to father children and males and their partners must be willing to use highly effective methods of contraception while on protocol treatment. Males must not donate sperm while on protocol treatment and for at least 12 weeks following the last dose of protocol treatment.\n\nHighly effective methods include the following:\n\n* Intrauterine device\n* Bilateral tubal occlusion\n* Vasectomized partner\n* Sexual abstinence If the highly effective contraceptive methods are contraindicated or strictly declined by the patient, or in the event of sexual activity of low frequency, a combination of male condom with cap, diaphragm, or sponge with spermicide (double-barrier methods) is also considered an acceptable birth control method. Local regulation\u002Fguidelines are to be followed with regard to highly effective birth control method, if more restrictive\n\n  * STEP 1: Patient must meet all Step 0 Pre-Registration eligibility criteria at the time of their Step 1 randomization\n  * STEP 1: Patient must not have had any major surgery or radiotherapy within 14 days prior to Step 1 randomization\n  * STEP 1: Patient must have a Recurrence Score (RS) of 0-25 from Oncotype DX testing from diagnostic biopsy or surgical specimen as reported by the Exact Sciences assay","ALL","18 Years",{"count":19,"type":20},1978,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.",[26,27,28,29,30],"Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Estrogen Receptor-Positive Breast Carcinoma","HER2-Negative Breast Carcinoma","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":20},"2027-02-14",{"date":39,"type":20},"2029-07-31",{"name":41,"class":42},"National Cancer Institute (NCI)","NIH",59,{"id":45,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":47,"briefSummary":24,"conditions":48,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":54,"locationsCount":55},"100623064",{"count":19,"type":20},[23],[26,27,28,29,30],"2026-07-01",{"date":51,"type":35},"2026-07-02",{"date":37,"type":20},{"date":39,"type":20},{"name":41,"class":42},36,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":17,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100530282","phase-2-finding-the-best-tamoxifen-dose-for-breast-cancer-risk-reduction-in-premenopausal-women-renaissance-trial-100530282","NCT06184750","Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial","Inclusion Criteria:\n\n* Premenopausal women at the time of enrollment defined by any of the following:\n\n  * Age under 50 years and regular menstruation (most recent period within the past 3 months)\n  * Age under 50 years and continuous hormonal contraception use and at least one intact ovary\n  * Women who are not postmenopausal based on serum hormone levels. Women with estradiol =\\\u003C 30 pg\u002FmL, follicle-stimulating hormone (FSH) \\>= 30 IU\u002FmL are eligible\n* Women with any of the following:\n\n  * A history of unilateral estrogen receptor (ER) positive ductal carcinoma in situ (DCIS) with local therapy completed (as determined by treating physician recommendation and patient acceptance) at least 1 month prior to study entry. (The untreated breast will be the study breast, for both imaging and optional biopsy)\n  * Recent or prior lobular carcinoma in situ (LCIS), or any form of epithelial atypia, flat epithelial (FEA), atypical ductal hyperplasia (ADH), or atypical lobular hyperplasia (ALH)\n  * Are risk eligible for preventive medication based on a five-year risk of 1.7% or greater, estimated with a validated model: the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool, Tyrer-Cusick, Breast Cancer Surveillance Consortium. If the Tyrer-Cuzick model is used a ten-year risk of 3.4% or greater is acceptable\n  * Are tamoxifen-eligible by American Society of Clinical Oncology (ASCO) guidelines (\\>= 2-fold increased risk compared to peer if age \\>= 45 years, and \\>= 4-fold increased risk if age \\\u003C 45 years)\n  * A history of mantle radiotherapy\n  * A moderate penetrance germline pathogenic variant\n* Participants ≥ 18 and ≤ 55 years old will be enrolled. Our trial objectives are not relevant to females under 18 years of age since breast cancer is extraordinarily rare in this age group, and there are no guidelines regarding use of tamoxifen in children, even if know to be at very high risk for breast cancer when older. Because no dosing or adverse event (AE) data are currently available on the use of tamoxifen in participants \\\u003C 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status must be =\\\u003C 2 (Karnofsky \\>= 60%)\n* Human immunodeficiency virus (HIV)-infected patients are eligible to participate if they are on effective anti-retroviral therapy with undetectable viral load within the prior 6 months\n* Women with evidence of chronic hepatitis B virus (HBV) infection, are also eligible if the HBV viral load is undetectable; they may be on suppressive therapy, if indicated\n* Women with a history of hepatitis C virus (HCV) infection are eligible if treated and cured. For those who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Women with herpes simplex virus (HSV) infection are eligible if on chronic or as needed (due to a flare) suppressive antiviral therapy\n* Hormonal contraceptive users are eligible and should maintain the same oral contraceptive preparation throughout the duration of the trial. For women who have a levonorgestrel-coated intra-uterine device, removal for medical reasons will be allowed\n* The effects of tamoxifen on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because tamoxifen is known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n* Breast Imaging Reporting and Data System (BIRAD) 1 or 2. If BIRAD 0, follow-up diagnostic imaging must be BIRAD 1 or 2 or cleared clinically with radiology recommendation of return to annual screening\n* Women who are factor V leiden carriers and have not had a blood clot are eligible, if approved by their treating physician\n\nExclusion Criteria:\n\n* BIRADS breast density category A on most recent mammogram\n* History of selective estrogen receptor modulator (SERM) use within the past 5 years unless:\n\n  * Use was less than 6 months duration in the past 5 years and not used in the 1 year prior to enrollment OR\n  * Use was no greater than 2 months duration in the past 1 year and not used in the 6 months prior to enrollment\n* History of invasive breast cancer\n* Prior bilateral mastectomy or breast augmentation surgery including breast implants. Prior bilateral excisional surgical biopsy, mastopexy (breast lift) or mammoplasty (breast reduction) is allowed, as long as \\> 1 year has passed since the procedure\n* Women with \"mosaic mammographic screening views\", i.e., whose larger breast size precludes being imaged within a single mammographic screening view\n* Current use of a strong CYP3A4 inducer or a strong CYP2D6 inhibitor unless willing and able to discontinue use and switch to an alternative medication for the duration of participation, under the advice of their physician. If the physician believes the current medication cannot be replaced, the participant will not be eligible\n* Current use of Warfarin\n* Planning to become pregnant within the next two years. Potential study participants will be questioned about this and excluded if they are planning pregnancy over the next 20 months\n* History of thromboembolism, pulmonary embolism, thrombotic stroke, arterial thrombosis of the extremity or deep vein thrombosis. A history of superficial thrombophlebitis is allowed\n* History of uterine cancer or atypical uterine hyperplasia with uterus intact\n* Participants may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen\n* Uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study because tamoxifen a category D agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with tamoxifen. Breastfeeding should be discontinued if the mother is treated with tamoxifen\n* Women with known gene mutations associated with an increased risk for breast cancer such as BRCA1\u002F2, CDH1, PALB2, PTEN, STK11, or P53\n* Current use of sex hormones (estrogen, progesterone, or androgens), unless part of oral contraception pills\n* Prior invasive cancer, unless curatively treated, and all treatment was completed \\> 5 years prior to enrollment","FEMALE","55 Years",{"count":66,"type":20},200,[68],"PHASE2","This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.",[71,72,73,74,75,29],"Breast Atypical Ductal Hyperplasia","Breast Atypical Lobular Hyperplasia","Breast Carcinoma","Breast Ductal Carcinoma In Situ","Breast Lobular Carcinoma In Situ","2026-06-16",{"date":78,"type":35},"2026-06-17",{"date":80,"type":35},"2024-09-27",{"date":82,"type":20},"2028-09-30",{"name":41,"class":42},11,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":63,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100518244","phase-2-reishi-mushroom-extract-for-fatigue-andor-arthralgiasmyalgias-in-patients-with-breast-cancer-on-aromatase-inhibitors-100518244","NCT06028022","Reishi Mushroom Extract for Fatigue and\u002For Arthralgias\u002FMyalgias in Patients With Breast Cancer on Aromatase Inhibitors","Reishi Mushroom Extract for Fatigue and\u002For Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative\n* Fatigue ≥ 4\u002F10\n* Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. \\[Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed\\]; CDK 4\u002F6 inhibitors abemaciclib, ribociclib ARE allowed\n* Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)\n* On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)\n* If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* White blood cell count (WBC) ≥ 3,000\u002Fmm\\^3 (obtained ≤ 30 days prior to randomization)\n* Hemoglobin ≥ 10 g\u002FdL (obtained ≤ 30 days prior to randomization)\n* Platelet count ≥ 100,000\u002Fmm\\^3 (obtained ≤ 30 days prior to randomization)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)\n* Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)\n* Prothrombin time (PT)\u002Factivated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only\n* Provide informed consent\n* Ability to complete questionnaires\n* Willing to return to enrolling institution during the active monitoring phase of the study\n* Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and\u002For surgeon per local standards, prior to registration\n\nExclusion Criteria:\n\n* Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active\u002Funtreated hepatitis\n* Allergy to mushrooms\n* On anticoagulation medication or aspirin or having a known bleeding disorder\n* On any specific medication for fatigue (e.g., methylphenidate)\n* Metastatic cancer diagnosis (history of nodal metastases is allowed)\n* Chronic steroid use, unless on physiologic replacement doses\n* Current use of any medical mushrooms\n* On medications for diabetes\n* History of symptomatic hypotension\n* Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fhealthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems\n\n* Drugs which exhibit either \\>20% inhibition or \\>20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, \\& Theophylline\n* Taking olaparib\n* Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)\n* Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks",{"count":93,"type":20},80,[68],"This phase II trial tests how well Reishi mushroom extract works in treating fatigue and\u002For joint\u002Fmuscle pain (arthralgias\u002Fmyalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias\u002Fmyalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias\u002Fmyalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias\u002Fmyalgias in breast cancer patients receiving an AI.",[29],"2026-06-15",{"date":76,"type":35},{"date":100,"type":35},"2023-10-18",{"date":102,"type":20},"2027-09-15",{"name":104,"class":105},"Mayo Clinic","OTHER",23,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":63,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100546970","enhancing-skin-appearance-and-quality-of-life-in-breast-cancer-survivors-on-aromatase-inhibitor-therapy-100546970","NCT06401889","Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy","Inclusion Criteria:\n\n* \\* Female ≥ 18 years\n\n  * Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion\n  * Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and\u002For progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)\u002F College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)\n  * Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included\n  * Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period\n  * Willing and able to provide consent\n\nExclusion Criteria:\n\n* \\* Patients who have previously taken AIs\n\n  * Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent",{"count":114,"type":20},35,"OBSERVATIONAL","This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.",[118,119,26,120,121,29,122],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Breast Adenocarcinoma","Progesterone Receptor-Positive Breast Carcinoma","2026-05-18",{"date":125,"type":35},"2026-05-19",{"date":127,"type":35},"2024-07-19",{"date":129,"type":20},"2027-07-19",{"name":104,"class":105},1,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":63,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":131},"100557459","phase-2-high-cannabidiol-plant-extract-brc-001-to-improve-aromatase-inhibitor-induced-arthralgia-in-women-with-breast-cancer-100557459","NCT06538389","High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer","High Cannabidiol (CBD) Standardized Extract for Aromatase Inhibitor-Induced Arthralgia - A Randomized Controlled Double Blind Clinical Trial","Inclusion Criteria:\n\n* Documented informed consent of the participant\n* Age: ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) ≤ 2\n* Postmenopausal by last menses \\> 12 months or medically induced menopause in premenopausal women for AI therapy use\n* At least 5 years since other malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission\n* Ability to read and understand English, Spanish, or translations by interpreters for questionnaires\n* Histologically confirmed primary invasive adenocarcinoma of the breast or ductal carcinoma in situ of the breast\n\n  * Stage 0, I, II, or IIIA disease\n  * No metastatic disease\n* Must have undergone definitive breast cancer surgery and recovered\n* Must have completed adjuvant chemotherapy as applicable, including systemic chemotherapy, anti-HER2 therapy, and\u002For radiation therapy\n* Estrogen-receptor positive (ER+) and\u002For progesterone-receptor positive (PR+)\n* Currently taking a third-generation aromatase inhibitor (AI) (e.g., anastrozole \\[Arimidex (registered trademark)\\], letrozole \\[Femara (registered trademark)\\], or exemestane \\[Aromasin (registered trademark)\\]) for ≥ 90 days prior to registration with plans to continue for ≥ 180 days after registration\n* Must have a worst pain\u002Fstiffness of ≥ 4 on the Brief Pain Inventory (BPI) (item #2) that has started or increased with AI therapy\n\nExclusion Criteria:\n\n* \\\u003C 3 months since prior cannabinoid containing cannabis or hemp products including CBD, tetrahydrocannabinol (THC), Marinol, and Epidiolex and must agree to refrain from use from sources outside of this study\n* \\\u003C 28 days since prior investigational agents\n* Medical therapy, alternative therapy, or physical therapy for joint pain\u002Fstiffness within the past 30 days\n* Narcotic use within 14 days of registration\n* Patients may have received corticosteroid treatment; however, the following criteria apply:\n\n  * Patients must not have received oral or intramuscular corticosteroids within 28 days prior to registration\n  * Patients must not have received intra-articular steroids to the study, or any other, joint within 28 days prior to registration\n* Patients must not have received topical analgesics (e.g., capsaicin preparations) to the study joint or any other analgesics (e.g., opiates, tramadol; with exception of nonsteroidal anti-inflammatory drugs \\[NSAIDs\\] and acetaminophen) within 14 days prior to registration\n* History of bone fracture or surgery of the afflicted hands, knees, and\u002For other joints within 6 months prior to registration\n* Any uncontrolled illness including ongoing or active infection\n* Known allergies or contraindications to cannabis\n* Significantly impaired hepatic function (alanine aminotransferase \\[ALT\\] \\> 5 x upper limit of normal \\[ULN\\] or total bilirubin \\[TBL\\] \\> 2 x ULN) OR the ALT or aspartate aminotransferase (AST) \\> 3 x ULN and TBL \\> 2 x ULN (or international normalized ratio \\[INR\\] \\> 1.5\n* Grade 3+ renal impairment\n* Clinically significant lab abnormalities in ALT, AST, total bilirubin, hemoglobin, hematocrit, or creatinine or any other laboratory tests that in the opinion of the investigator would prevent the patient from safely participating in the study\n* Having current thoughts of suicide or self-harm or history of suicidal ideation or attempted suicide\n* Meeting Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria for current major psychiatric illness, such as bipolar disorder, major depression, or psychosis (including schizophrenia and affective psychosis)\n* History of seizure disorder\n* Concomitant administration with drugs that may interact adversely with CBD including warfarin, theophylline, amiodarone, anti-epileptic (e.g., clobazam, stiripentol, valproate, topiramate), anticonvulsant (e.g., diazepam, lamotrigine, phenytoin, ethosuximide, oxcarbazepine, pregabalin, tigabine, gabapentin); 3) barbiturate (e.g., phenobarbital, hexobarbital), benzodiazepine (e.g, chlordiazepoxide, clonazepam), opioid\u002Fnarcotic (e.g, codeine, morphine)\n* Concomitant administration of cyclin-dependent kinase 4\u002F6 inhibitors, such as abemaciclib, with AI therapy\n* Following a physical examination, the patient has any abnormalities that, in the opinion of the investigator would prevent the patient from safely participating in the study\n* Other active malignancy\n* Any other condition or medication use that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Participants unwilling to abstain from donation of blood during the study\n* Participants who plan to travel outside of the United States during the study period\n* Women with childbearing potential are not eligible to participate. The study is for postmenopausal women taking aromatase inhibitors for adjuvant endocrine therapy\n* Participants with cognitive impairment are excluded due to dose titration instructions and completion of questionnaires\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":55,"type":20},[68],"This phase II trial tests the effectiveness of cannabidiol (CBD) plant extract (BRC-001) in improving joint stiffness and pain (arthralgia) in women with breast cancer taking aromatase inhibitors (AIs). AIs lower blood levels of estrogen in postmenopausal women to reduce breast cancer recurrence. Women on AI therapy may experience joint stiffness, pain and arthritis symptoms as a side effect of the medication. Some women stop AI therapy due to these side effects and do not receive the maximum benefit from the medication. CBD is derived from the same plant family as marijuana but is not associated with a \"high\" or mind-altering effect and is not habit-forming. Research in animals and humans indicates that CBD might decrease inflammation in joint tissues and may help reduce chronic pain in ailments such as arthritis. BRC-001 may reduce joint pain in women with breast cancer taking AIs.",[118,119,26,27,121,74,29,122],"2026-04-27",{"date":145,"type":35},"2026-04-30",{"date":147,"type":35},"2024-08-26",{"date":149,"type":20},"2027-01-24",{"name":151,"class":105},"City of Hope Medical Center",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":63,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":131},"100550730","phase-2-turkey-tail-mushroom-for-treating-post-menopausal-women-with-her2-negative-er-positive-breast-cancer-undergoing-surgery-100550730","NCT06450873","Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery","A Phase 2 Pilot Window of Opportunity Study Turkey Tail Mushrooms (TTM) (Trametes Versicolor) in Post-Menopausal Women With HER2 (-) ER (+) Breast Cancer Planning to Undergo Surgical Therapy","Inclusion Criteria:\n\n* Women ≥ 18 years of age\n* Histological confirmation of ER+, HER2- breast cancer, newly diagnosed and tissue available for central confirmation of Ki-67 measurement. Subjects are eligible if they have a Ki-67 of ≥10%. Ki-67 will be repeated for patients who have had this done externally.\n* Scheduled for definitive breast surgery\n* Detectable disease as defined by mammography, breast ultrasound of greater than 5mm in size.\n\n  * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible\n* Post menopausal as defined by:\n\n  * Self-reported last menstrual period greater than 12 months, or\n  * Bilateral oophorectomy, or\n  * Follicle stimulating hormone (FSH) \\>20 mIU\u002FmL, and estradiol level ≤ 20 pg\u002FmL\n* Not taking aromatase inhibitor or a selective estrogen receptor modifier\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 obtained ≤ 90 days prior to registration\n* Platelet count ≥ 100,000\u002Fmm\\^3 (obtained ≤ 90 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3 (obtained ≤ 90 days prior to registration)\n* Hemoglobin ≥ 11 g\u002FdL (obtained ≤ 90 days prior to registration)\n* Serum transaminase \\[alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\\] ≤ 1.2 x upper limit of normal (ULN) (obtained ≤ 90 days prior to registration)\n* Alkaline phosphatase ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration)\n* Serum creatinine ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration)\n* Provide written informed consent\n* Ability to complete the Symptom Experience Diary by themselves or with assistance\n\nExclusion Criteria:\n\n* Ki-67 of \\\u003C10%\n* Current use of any medicinal mushrooms\n* Patient with locally advanced cancer who will require neoadjuvant therapy or metastatic cancer\n* Currently on systemic chemotherapy\n* Concurrent endocrine therapy (selective estrogen receptor modifiers or aromatase inhibitors)\n* Allergy to mushrooms\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Immunocompromised patients\n* Patients known to be HIV positive and currently receiving antiretroviral therapy.\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n* Other active malignancy 3 years prior to registration\n\n  * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix\n  * NOTE: If there is a history of prior malignancy, they must not be receiving chemotherapy treatment for their cancer",{"count":160,"type":20},40,[68],"This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.",[29,30],"2026-03-26",{"date":166,"type":35},"2026-03-31",{"date":168,"type":35},"2024-10-25",{"date":170,"type":20},"2028-04-30",{"name":104,"class":105},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100536069","phase-2-stereotactic-body-radiation-therapy-and-fes-petct-imaging-for-the-treatment-of-oligoprogressive-estrogen-receptor-positive-metastatic-breast-cancer-100536069","NCT06260033","Stereotactic Body Radiation Therapy and FES PET\u002FCT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Age: ≥ 18 years\n* Female or male\n* Eastern Cooperative Oncology Group (ECOG) ≤ 2\n* Ability to read and understand English or Spanish for questionnaires\n* Histologically confirmed ER+ (any progesterone receptor \\[PR\\] and human epidermal growth factor receptor 2 \\[HER2\\] status is allowed) metastatic breast cancer\n* The presence of metastatic breast cancer at the time of study entry with progression in 1-4 lesions (including new lesions). Patients that have disease progression in the breast and\u002For ipsilateral axilla will be considered to have only 1 site of progression even if multiple nodules\u002Flymph nodes are present. Patients with progression in \\> 4 lesions are not allowed. Patients with current progression of malignant pleural effusions, malignant ascites, abdominal carcinomatosis, and\u002For lymphangitic pulmonary involvement are considered to have \\> 4 metastases (Note that patients with a history of these conditions earlier in the disease course with no evidence of progression of these conditions are eligible.)\n* Evidence of extracranial disease progression in 1-4 discrete lesions will be defined by either of the following:\n\n  * Progression of disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or PET Response Criteria in Solid Tumors (PERCIST) v 1.0 criteria OR\n  * Progression of disease in at least 1 but up to 4 lesions as determined by the patient's treating oncologists such that the treating oncologist recommends changing to the next line systemic therapy. Note that a patient may not technically meet RECIST v 1.1 criteria for disease progression in this setting\n* SBRT must be feasible for all progressing lesions. Feasibility includes but is not limited to:\n\n  * All progressing lesions must have distinct borders AND\n  * Progressing lesions may not be located within 3 cm of previously irradiated critical structures such as the spinal cord, brachial plexus, brainstem, stomach, and\u002For small\u002Flarge bowel that would render the metastasis unsafe to target with SBRT per the treating radiation oncologist\n* Patients with prior treated brain metastases that are stable are allowed. Patients must not have intracranial disease progression. Patients with prior or current leptomeningeal disease are not allowed\n* All progressing lesions must be amenable to stereotactic body radiation therapy to a dose of 30 Gy to 40 Gy in 3 to 5 fractions per the treating radiation oncologist\n* Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test, If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Has received at least one line, but not more than three lines, of systemic therapy for metastatic disease\n* Patients may not have received chemotherapy, radiation therapy, biological therapy, immunotherapy, or other anti-cancer treatment within 7-14 days of the start of study therapy (SBRT) at the discretion of treating physician. Chemotherapy must be held during study therapy and can resume 7-14 days after completion of all study therapy (SBRT) at the discretion of treating physician. (Patients may continue anti-endocrine\u002Fhormone therapy before, during and after study therapy at the discretion of the treating medical oncologist.)\n* Clinically significant uncontrolled illness such that the patient is no longer a candidate for systemic therapy\n* Prior or concurrent malignancy. Prior malignancies with a low probability of recurrence requiring treatment such as the following are allowed: carcinoma in situ of the cervix, non-melanoma skin cancer, and low grade (Gleason score ≤ 6 = Gleason group 1) localized prostate cancer. Prior malignancies not listed require principal investigator (PI) approval\n* Patients that have only liver metastases will not be allowed\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":180,"type":20},18,[68],"This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body (metastatic) and has limited disease progression (oligoprogression). Currently, the standard of care for breast cancer patients with oligoprogressive disease is to change systemic therapy when progression occurs. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses (fractions) given over several days. This type of radiation therapy helps spare normal tissue and has been shown to improve survival. SBRT may kill more tumor cells and allow patients with oligoprogressive ER + metastatic breast cancer to continue taking current systemic treatment.\n\nThis trial also tests how well ER targeted positron emission tomography (PET)\u002F computed tomography (CT) imaging, using FES, works in identifying progressive disease in patients with ER + metastatic breast cancer. FES, a radiolabeled substance, binds to estrogen receptors and gives off radiation that can be detected by a PET scan. The PET scan, an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, FES, forms an image that shows where tumor cells with estrogen receptors can be found in the body. CT images use x-rays to provide an exact outline of organs. FES PET\u002FCT may improve identification of progressive disease in patients with ER + metastatic breast cancer.",[184,29,185],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","2025-10-02",{"date":188,"type":35},"2025-10-06",{"date":190,"type":35},"2024-07-23",{"date":192,"type":20},"2026-10-29",{"name":151,"class":105},2]